Yıl: 2021 Cilt: 19 Sayı: 2 Sayfa Aralığı: 122 - 129 Metin Dili: İngilizce İndeks Tarihi: 18-11-2022

Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening

Öz:
Background: First trimester prenatal screening gives the risk rates associated with aneuploidies. Measurement uncertainty is defined as a magnitude showing distribution of the measured values. The aim of this study is to investigate the effects of measurement uncertainty on prenatal screening and compare two different measurement uncertainty guidelines which suggest different equations. Material and Methods: This retrospective study was performed with results of 544 patients. Uncertainties of free-βsubunit human Chorionic Gonadotropin (free β-hCG) and Pregnancy Associated Protein-A (PAPP-A) were calculated as defined by AACB and Nordtest guides.The best-case and the worst-case scenarios were created for risk rates of trisomies. New risks were recalculated by adding and subtracting uncertainty values from free β-hCG and PAPP-A. Results: The number of patients who have a risk rate >1:1500 and to be subject to further investigation was 58. This number decreased to 38 and 36 with best-case scenarios, while the number increased to 94 and 99 with worst-case scenarios with the uncertainty values obtained from the AACB and Nordtest guidelines, respectively (P<0.005). There was a significant difference between median risks of the patients with two guidelines with best-case and the worst-case scenarios(P<0.005). Conclusions: When a result is calculated with multiple parameters, calculation of uncertainty and reporting with the result may significantly affect the outcome. The measurement uncertainty equation to be selected is also important.
Anahtar Kelime:

Birinci Trimester Prenatal Tarama Testinde Ölçüm Belirsizliğinin Değerlendirilmesi

Öz:
Amaç: Birinci trimester prenatal tarama, anöploidiler ile ili şkili risk oranlarını verir. Ölçüm belirsizli ği ise, ölçülen değerlerin dağılımını gösteren bir büyüklük olarak tan ımlanır. Bu çal ışmanın amacı, ölçüm belirsizliğinin doğum öncesi taramaya etkilerini ara ştırmak ve farkl ı denklemler öneren iki farkl ı ölçüm belirsizliği kılavuzunu karşılaştırmaktır. Gereç ve Yöntem: Bu retrospektif çal ışma 544 hastanın sonuçlar ıyla yapıldı. Serbest beta Koryonik Gonadotropin (serbest β-hCG) ve Gebelik İlişkili Protein-A (PAPP-A) beli rsizlikleri AACB ve Nordtest kılavuzları tarafından tanımlandığı şekilde hesaplandı. Trizomi risk oranları için en iyi ve en kötü durum senaryoları oluşturuldu. Serbest β-hCG ve PAPP-A'nın belirsizlik değerleri mevcut değerlere eklenerek ve çıkarılarak yeni riskler yeniden hesaplandı. Bulgular: Risk oranı> 1: 1500 olan ve ileri incelemeye tabi tutulacak hasta say ısı 58 idi. Bu say ı sırasıyla AACB ve Nordtest kılavuzları ile hesaplanan sonuçlarla, en iyi senaryolarda 38 ve 36'ya düşerken, en kötü senaryolarla 94 ve 99'a yükseldi (P <0.005). En iyi durum ve en kötü durum senaryolarına sahip iki k ılavuza sahip hastaların medyan riskleri aras ında anlamlı bir fark vard ı (P <0.005). Sonuç: Ölçüm belirsizli ğinin sonuçla birlikte raporlanmas ı klinik kararı etkileyebilir. Çal ışmamızda olduğu gibi bir sonuç birden fazla parametre ile hesaplandığında, belirsizliğin hesaplanması ve sonuçla birlikte raporlanmas ı sonucu önemli ölçüde etkileyebilir. Seçilecek ölçüm belirsizli ği denklemi de önemlidir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Cunningham FG, Leveno KJ, Bloom S., Gilstrap L, Williams Obstetrics. 23th edition. New York: McGraw-Hill Education, 2014.
  • 2. Stefanovic V, Äyräs O, Eronen M, Paavonen J, Tikkanen M., Clinical utility of nuchal translucency screening, Research and Reports in Neonatology,13 October 2014 Volume 2014:4 Pages 169—176.
  • 3. Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound in Obstetrics & Gynecology. 2015 May;45(5):530-8.
  • 4. Durkovi J, Ubavi M, Durkovi M, Kis T, Prenatal Screening Markers For Down Syndrome: Sensitivity, Specificity, Positive And Negative Expected Value Method, J Med Biochem 37: 62–66, 2018.
  • 5. Dey, M., Sharma, S., Aggarwal, S., Prenatal Screening Methods for Aneuploidies, N Am J Med Sci. 2013 Mar; 5(3): 182–190.
  • 6. Nicolaides KH.,Multicenter study of first-trimester screening for trisomy21 in 75821 pregnancies: results and estimation of potential impact of individual risk-orientated two-stage first-trimester screening.Ultrasound Obstet Gynecol.2005 Mar; 25(3):221-6.
  • 7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy.Obstet Gynecol. 2007 Dec;110(6):1459-67.
  • 8. Adams TM. G104 - A2LA Guide for Estimation of Measurement Uncertainty In Testing. A2LA. July 2002.
  • 9. Badrick T, Hawkins RC, Wilson SR, Hickman PE.Uncertainty of Measurement: What it is and What it Should Be, Clin Biochem Rev. 2005 Nov; 26(4): 155–158.
  • 10. Braga F, Panteghini M. The utility of measurement uncertainty in medical laboratories. Clin Chem Lab Med. 2020 Mar 3;58(9):1407-1413.
  • 11. Lee JH, Choi JH, Youn JS, Cha YJ, Song W, Park AJ. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty. Clin Chem Lab Med. 2014 DOI 10.1515/cclm-2014-0801.
  • 12. Milinković N., Ignjatović S., Šumarac Z., Majkić-Singh N., Uncertainty of Measurement in Laboratory Medicine, J Med Biochem. 2018 Jul; 37(3): 279–288.
  • 13. White GH, Farrance I; AACB Uncertainty of Measurement Working Group. Uncertainty of measurement in quantitative medical testing: a laboratory implementation guide. Clin Biochem Rev. 2004;25(4):S1-S24.
  • 14. Magnusson B, Näykki T, Hovind H, Krysell M. NT Technical Report Handbook for Calculation of Measurement Uncertainty in Environmental Laboratories Version 3.1. Nordtest. May 2012
  • 15. Plebani M, Sciacovelli L, Bernardi D, Aita A, Antonelli G,Padoan A. What information on measurement uncertainty should be communicated to clinicians, and how? Clinical Biochemistry, July 2018; 57:18- 22.
APA BOZKURT YAVUZ H, Yaman H, KARAHAN S, katkat m, Aliyazıcıoğlu Y, Orem A (2021). Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. , 122 - 129.
Chicago BOZKURT YAVUZ Hatice,Yaman Hüseyin,KARAHAN SÜLEYMAN CANER,katkat merve,Aliyazıcıoğlu Yüksel,Orem Asım Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. (2021): 122 - 129.
MLA BOZKURT YAVUZ Hatice,Yaman Hüseyin,KARAHAN SÜLEYMAN CANER,katkat merve,Aliyazıcıoğlu Yüksel,Orem Asım Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. , 2021, ss.122 - 129.
AMA BOZKURT YAVUZ H,Yaman H,KARAHAN S,katkat m,Aliyazıcıoğlu Y,Orem A Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. . 2021; 122 - 129.
Vancouver BOZKURT YAVUZ H,Yaman H,KARAHAN S,katkat m,Aliyazıcıoğlu Y,Orem A Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. . 2021; 122 - 129.
IEEE BOZKURT YAVUZ H,Yaman H,KARAHAN S,katkat m,Aliyazıcıoğlu Y,Orem A "Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening." , ss.122 - 129, 2021.
ISNAD BOZKURT YAVUZ, Hatice vd. "Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening". (2021), 122-129.
APA BOZKURT YAVUZ H, Yaman H, KARAHAN S, katkat m, Aliyazıcıoğlu Y, Orem A (2021). Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. Türk Klinik Biyokimya Dergisi, 19(2), 122 - 129.
Chicago BOZKURT YAVUZ Hatice,Yaman Hüseyin,KARAHAN SÜLEYMAN CANER,katkat merve,Aliyazıcıoğlu Yüksel,Orem Asım Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. Türk Klinik Biyokimya Dergisi 19, no.2 (2021): 122 - 129.
MLA BOZKURT YAVUZ Hatice,Yaman Hüseyin,KARAHAN SÜLEYMAN CANER,katkat merve,Aliyazıcıoğlu Yüksel,Orem Asım Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. Türk Klinik Biyokimya Dergisi, vol.19, no.2, 2021, ss.122 - 129.
AMA BOZKURT YAVUZ H,Yaman H,KARAHAN S,katkat m,Aliyazıcıoğlu Y,Orem A Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. Türk Klinik Biyokimya Dergisi. 2021; 19(2): 122 - 129.
Vancouver BOZKURT YAVUZ H,Yaman H,KARAHAN S,katkat m,Aliyazıcıoğlu Y,Orem A Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening. Türk Klinik Biyokimya Dergisi. 2021; 19(2): 122 - 129.
IEEE BOZKURT YAVUZ H,Yaman H,KARAHAN S,katkat m,Aliyazıcıoğlu Y,Orem A "Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening." Türk Klinik Biyokimya Dergisi, 19, ss.122 - 129, 2021.
ISNAD BOZKURT YAVUZ, Hatice vd. "Evaluation of Measurement Uncertainty of First Trimester Prenatal Screening". Türk Klinik Biyokimya Dergisi 19/2 (2021), 122-129.